What to know about melanotan II
Melanotan II is an unapproved “tanning peptide” that stimulates melanin signaling. The hard part is not the biology. It’s the safety, skin-risk, and unregulated supply chain.
Tag
Safety
When peptides move from papers to people, safety is the whole story. This tag collects safety questions, adverse event signals, and reality checks.
Start here
The facts behind Reta
Retatrutide, often called “Reta,” is an investigational triple-agonist weight-loss drug. Early trials look impressive, but the main questions are long-term safety, tolerability, and what happens outside tightly run studies.
Peptides that can dial down cortisol
A few human peptides have evidence for blunting cortisol responses in specific settings. This is what we actually know, what’s still unclear, and why ‘lower cortisol’ is a tricky goal.
Kisspeptin and gonadorelin: upstream hormone signals, not casual wellness tools
Kisspeptin and gonadorelin have real clinical lineage, but they sit high in the hormone control system. If use expands through compounding channels, careful monitoring and conservative claims will matter.
How peptide hype evolves (and a verification checklist)
A practical field guide to how new peptides and ‘next-gen analogs’ spread online, what usually gets exaggerated, and the minimum evidence needed before you treat marketing as reality.
Is BPC-157 safe?
A cautious question page on what is known, what is speculative, and what remains uncertain about BPC-157 safety.
BPC-157
A research-stage recovery peptide discussed for soft tissue healing and gut protection.
When obesity meds get blamed in the OR
A perioperative review argues that adverse effects from modern anti-obesity drugs can be mistaken for surgical or anesthesia complications, raising the bar for documentation, holds, and post-op restarts.
GLP‑1 drugs during chemo: the monitoring gap
A new supportive-care commentary argues that as GLP‑1 drugs become common, cancer treatment teams may need routine nutrition and body-composition monitoring to avoid avoidable toxicity and dose changes.
A new look at GLP‑1s and suicidality risk
A large register study using two comparator cohorts plus a self-controlled design found no increased rate of suicide or suicide attempts after starting GLP‑1 receptor agonists.
GLP-1 drugs and depression: a meta-analysis finds a signal, but the heterogeneity is huge
An open-access meta-analysis reports higher odds of depression-related adverse events among GLP-1 receptor agonist users (OR 1.49), but between-study heterogeneity is extreme (I² ~99%), which limits how literally the pooled number should be taken.
A new tirzepatide safety meta-analysis, focused on higher-risk patients
A systematic review and meta-analysis of 21 placebo-controlled trials in patients at increased cardiovascular risk found no clear difference in serious adverse events with tirzepatide, while gastrointestinal side effects remained more common. Mortality evidence was sparse.
Pancreatitis fears and GLP‑1s: the cleanest data so far
A living meta-analysis of placebo-controlled RCTs of semaglutide and tirzepatide lands near ‘no signal’ for acute pancreatitis. That’s reassuring, but rare-event uncertainty is exactly why this concern keeps coming back.
For short bowel syndrome, GLP‑2 drugs work—and the side effects matter
A 2026 review of glucagon-like peptide therapies in short bowel syndrome puts the spotlight where patients live: side effects, monitoring, and the trade-offs that come with reducing dependence on IV nutrition.
A ‘next‑gen BPC‑157’ is trending. Here’s how to verify ‘pentadecapeptide arginate’ before treating it as real
“Pentadecapeptide arginate” is being promoted online as a stabilized, enhanced BPC‑157 analog. The clean way to read the trend is as a verification exercise: what exactly is the compound, what evidence exists, and what would need to be true for the marketing claims to be more than adjectives.
When GLP‑1s meet pregnancy planning
A 2026 clinical perspectives paper pulls together what’s known (and unknown) about GLP‑1 drugs and fertility, contraception reliability, and pregnancy planning—plus what the drug labels actually say about washout and birth control.
GLP‑1 drugs in type 1 diabetes: the safety signal gets sharper
A huge electronic health record analysis suggests GLP‑1 receptor agonists in type 1 diabetes may be linked to fewer major heart and kidney events without a clear increase in hospitalized DKA—a promising signal that still isn’t a randomized trial.
What people say GLP‑1 side effects feel like (and why Reddit data isn’t the same thing as safety data)
A 2026 medRxiv preprint analyzed 410,198 Reddit posts about semaglutide and tirzepatide. GI symptoms dominated, but the real value is in seeing which experiences people choose to write about—and which clusters might deserve more explicit measurement.